Breaking the biopharma glass ceiling isn’t just a moral issue; it’s a shareholder issue. McKinsey reported in a recent study that companies in the top quartile for gender diversity are 15 percent more likely to generate financial returns above the industry average; those in the top quartile for racial and ethnic diversity are 35 percent more likely to do so.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,